Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma

Authors: Jie Chen, Qu Lin, Jing-Yun Wen, Xing Li, Xiao-Kun Ma, Xin-Juan Fan, Qin-Hua Cao, Min Dong, Li Wei, Zhan-Hong Chen, Xiao-Yun Li, Tian-Tian Wang, Quentin Liu, Xiang-Bo Wan, Yan-Fang Xing, Xiang-Yuan Wu

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

Others and we have demonstrated that hypoxia-inducible factor 1α (HIF-1α) and transcriptionally upregulated Aurora-A are required for disease progression in several tumors. We investigated the clinicopathological value of HIF-1α and Aurora-A in primary duodenal adenocarcinoma (PDA). Using immunohistochemistry, we evaluated Aurora-A and HIF-1α expression semiquantitatively in 140 PDA cases. There were 76 cases from one institute that formed the training set; 64 cases from another two institutes were used as the testing set to validate the prognostic value of Aurora-A and HIF-1α expression. Aurora-A expression was high or sufficient in the tumor zone, whereas expression was low in the adjacent normal epithelia. High Aurora-A expression, identified using the training set receiver operator characteristic (ROC) analysis-generated cutoff score, predicted poorer overall survival both in the testing set (18.0 vs. 45.1 %, P = 0.001) and training set (23.1 vs. 53.9 %, P = 0.011). Multivariate Cox regression confirmed that Aurora-A was an independent prognostic factor. Contrary to previous studies, we did not detect any correlation between Aurora-A and HIF-1α. Survival analysis showed that HIF-1α level was not correlated with patient outcome (P = 0.466). Activation of Aurora-A, an independent negative prognostic biomarker, might be used to identify particular PDA patients for more selective therapy.
Literature
1.
Zenklusen HR, Landmann J, Feess A, Durig M, Kasper M, Oberholzer M. Primary duodenal carcinoma arising in a non-vaterian tubulo-villous adenoma. A case report with immunocytochemical analysis and review of the literature. Virchows Arch A Pathol Anat Histopathol. 1989;414:529–33.CrossRefPubMed
2.
Barnes Jr G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994;1:73–8.CrossRefPubMed
3.
Howe JR, Karnell LH, Menck HR, Scott-Conner C. The american college of surgeons commission on cancer and the american cancer society. Adenocarcinoma of the small bowel: review of the national cancer data base, 1985–1995. Cancer. 1999;86:2693–706.CrossRefPubMed
4.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science. 1987;235:177–82.CrossRefPubMed
5.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed
6.
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.CrossRefPubMed
7.
Yang C, Tang X, Guo X, Niikura Y, Kitagawa K, Cui K, et al. Aurora-b mediated atm serine 1403 phosphorylation is required for mitotic atm activation and the spindle checkpoint. Mol Cell. 2011;44:597–608.PubMedCentralCrossRefPubMed
8.
Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004;14:29–36.CrossRefPubMed
9.
Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999;59:2041–4.PubMed
10.
Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, et al. Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene. 2006;25:7148–58.CrossRefPubMed
11.
12.
Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA. Human tpx2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 2002;158:617–23.PubMedCentralCrossRefPubMed
13.
Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the lim protein ajuba, are required for mitotic commitment in human cells. Cell. 2003;114:585–98.CrossRefPubMed
14.
Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA. Mitotic activation of the kinase Aurora-A requires its binding partner bora. Dev Cell. 2006;11:147–57.CrossRefPubMed
15.
Shao S, Wang Y, Jin S, Song Y, Wang X, Fan W, et al. Gadd45a interacts with Aurora-A and inhibits its kinase activity. J Biol Chem. 2006;281:28943–50.CrossRefPubMed
16.
17.
Klein A, Flugel D, Kietzmann T. Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and hif-1. Mol Biol Cell. 2008;19:3667–75.PubMedCentralCrossRefPubMed
18.
Kao SY, Chen YP, Tu HF, Liu CJ, Yu AH, Wu CH, et al. Nuclear stk15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro. J Pathol. 2010;222:99–109.PubMed
19.
Reiter R, Gais P, Jutting U, Steuer-Vogt MK, Pickhard A, Bink K, et al. Aurora kinase A messenger rna overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:5136–41.CrossRefPubMed
20.
Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, et al. Relationship of increased Aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer. 2012;106:748–55.PubMedCentralCrossRefPubMed
21.
Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Belien JA, et al. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013;109:2445–52.PubMedCentralCrossRefPubMed
22.
Xu J, Wu X, Zhou WH, Liu AW, Wu JB, Deng JY, et al. Aurora-a identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS ONE. 2013;8:e56919.PubMedCentralCrossRefPubMed
23.
Wan XB, Fan XJ, Huang PY, Dong D, Zhang Y, Chen MY, et al. Aurora-A activation, correlated with hypoxia-inducible factor-1alpha, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci. 2012;103:1586–94.CrossRefPubMed
24.
Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8:1798–810.PubMedCentralCrossRefPubMed
25.
Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, et al. Elevated beclin 1 expression is correlated with hif-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy. 2010;6:395–404.CrossRefPubMed
26.
Cui SY, Huang JY, Chen YT, Song HZ, Huang GC, De W, et al. The role of Aurora A in hypoxia-inducible factor 1alpha-promoting malignant phenotypes of hepatocelluar carcinoma. Cell Cycle. 2013;12:2849–66.PubMedCentralCrossRefPubMed
27.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.CrossRefPubMed
28.
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of her-2/neu oncogene amplification in primary breast cancer. The south Australian breast cancer study group. J Clin Oncol. 1993;11:1936–42.PubMed
29.
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960–70.PubMed
30.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med. 2001;344:783–92.CrossRefPubMed
31.
Dutertre S, Descamps S, Prigent C. On the role of Aurora-A in centrosome function. Oncogene. 2002;21:6175–83.CrossRefPubMed
32.
Yamamoto S, Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Iwase H. A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer. BMC Cancer. 2013;13:217.PubMedCentralCrossRefPubMed
33.
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. Vx-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262–7.CrossRefPubMed
34.
Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, et al. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for mln8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res. 2011;71:675–85.CrossRefPubMed
35.
Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006;66:4996–5002.CrossRefPubMed
36.
Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, et al. Phase I dose escalation study of mk-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;67:305–14.PubMedCentralCrossRefPubMed
37.
Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A. 2009;106:19485–90.PubMedCentralCrossRefPubMed
38.
Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih Ie M, Wong KK, et al. Ras promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and brca2 in midbody during cytokinesis. Int J Cancer. 2013;133:275–85.CrossRefPubMed
39.
Hamidi T, Cano CE, Grasso D, Garcia MN, Sandi MJ, Calvo EL, et al. Nupr1-Aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. Clin Cancer Res. 2012;18:5234–46.CrossRefPubMed
40.
Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, et al. Phlda1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci. 2011;124:2711–22.CrossRefPubMed
41.
Jiang S, Katayama H, Wang J, Li SA, Hong Y, Radvanyi L, et al. Estrogen-induced Aurora kinase-A (AURKA) gene expression is activated by gata-3 in estrogen receptor-positive breast cancer cells. Horm Cancer. 2010;1:11–20.PubMedCentralCrossRefPubMed
42.
Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by Aurora kinase A induces mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36:55–62.CrossRefPubMed
Metadata
Title
Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma
Authors
Jie Chen
Qu Lin
Jing-Yun Wen
Xing Li
Xiao-Kun Ma
Xin-Juan Fan
Qin-Hua Cao
Min Dong
Li Wei
Zhan-Hong Chen
Xiao-Yun Li
Tian-Tian Wang
Quentin Liu
Xiang-Bo Wan
Yan-Fang Xing
Xiang-Yuan Wu
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2215-3

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis

Research Article

The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women

Research Article

RETRACTED ARTICLE: Relationships between genetic polymorphisms in inflammation-related factor gene and the pathogenesis of nasopharyngeal cancer

Research Article

Role of IL-17F T7488C polymorphism in carcinogenesis: a meta-analysis

Review

Podoplanin—a novel marker in oral carcinogenesis

Research Article

No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits